AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05733442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHaRRM-CN
Description: The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
Study NCT04990934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semistructured Interview
Description: Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
Study NCT06137456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeletal robotic therapy for walking.
Description: Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
Study NCT06137456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
Study NCT05828017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Standard Curve
Description: Our current hearing aids which will be programmed to our standard frequency response curve.
Study NCT05828017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #1
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study NCT05668065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac/CoronaVac
Description: Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
Study NCT05668065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac/BNT162b2
Description: First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2
Study NCT05076812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measure plasma level of interleukin 38 by ELISA kit
Description: draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Study NCT01384435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Study NCT04800991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhexium Onco Nutrition
Description: The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body
Study NCT01384435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05213065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block with 0.5% bupivacaine
Description: Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
Study NCT05213065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine ganglion block with saline
Description: Repetitive SPG blockade using saline delivered with the Tx360® device.
Study NCT05719701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-490
Description: Several dose groups of ICP-490 are planned for the dose exploration.
Study NCT05719701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
Study NCT05356546 — intervention group
Intervention type: OTHER
Intervention: Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection
Description: Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
Study NCT06387797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Adults (CMA+)
Description: Six cooking classes + enhanced elements, such as diabetes-specific nutrition and cooking information, and online educational information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. This arm will have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up. Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
Study NCT00011037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)120(B,MN)GNP (vCP1452)
Description: 1 x 10\^ 7 TCID50 administered intramuscularly
Study NCT00011037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MN rgp120/HIV-1
Description: 0.6 mg administered intramuscularly
Study NCT00011037 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC(2)120(B,MN)GNP (vCP1452) placebo
Description: ALVAC placebo administered intramuscularly
Study NCT00011037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MN rgp120/HIV-1 placebo
Description: Alum placebo administered intramuscularly
Study NCT00011037 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MN rgp120/HIV-1 placebo
Description: Alum placebo administered intramuscularly
Study NCT06387797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cooking Matters for Adults (CMA)
Description: Participants will attend cooking and educational sessions once per week for 6 weeks. In addition, they will receive recipes and produce boxes with instructions to prepare the recipe at some point prior to their next class. They will also be invited to the online Google Classroom site where all intervention materials will be housed for their convenience. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up (kits provided at the final cooking class, for a total of 6 fecal samples per participant). Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
Study NCT00012766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated team care
Study NCT05821023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
Study NCT05821023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
Study NCT06266676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro-course
Description: The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
Study NCT06266676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slide presentation
Description: Provide online presentations.
Study NCT05880433 — intervention group
Intervention type: DEVICE
Intervention: NIRS(INVOS 5100; Covidien Somanetics, Troy, MI
Description: NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
Study NCT05199935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
Study NCT05043753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
Description: Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016).
Study NCT06291480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurologic Music Therapy
Description: Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
Study NCT04966507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouthwash Product
Description: COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Study NCT04966507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biotene Mouthwash
Description: Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Study NCT05074459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab Mammalian Cell Line
Description: Concentrate for solution for IV infusion
Study NCT05074459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptinezumab Yeast Cell Line
Description: Concentrate for solution for IV infusion
Study NCT04985877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult light 300
Description: 2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proposed study design and randomization scenarios
Description: Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proposed study design and randomization scenarios
Description: Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments
Description: We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments
Description: We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Description: In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
Study NCT05610527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Description: In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
Study NCT04774159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG Oral Tablet
Description: Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label.
Study NCT04774159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine-Placebo
Description: Colchicine-Placebo tablet
Study NCT06336772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Shaype
Description: Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
Study NCT06336772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Volux
Description: Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
Study NCT05877534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual tailored exercise
Description: A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
Study NCT06391879 — intervention group
Intervention type: GENETIC
Intervention: Single cell sequencing, whole genome and metabolomic sequencing
Description: The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
Study NCT04796168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting (plaster of paris)
Description: Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
Study NCT05809843 — intervention group
Intervention type: DEVICE
Intervention: hybrid artificial pancreas systems (CSII)
Description: artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
Study NCT06514547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugate Pneumococcal Vaccine 20 (PCV20)
Description: Vaccine
Study NCT04843761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Study NCT04843761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Study NCT04843761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Study NCT04843761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aviptadil
Description: Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
Study NCT04843761 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aviptadil
Description: Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
Study NCT04843761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
Study NCT04843761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study NCT04843761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study NCT05582993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF administered by intravenous injection.
Study NCT05582993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: ADVATE administered by intravenous injection.
Study NCT06444581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Skills Schools
Description: Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
Study NCT05494996 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
Study NCT04848272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Monoclonal antibody that targets active plasma kallikrein
Study NCT04848272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline control
Study NCT06172647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
Study NCT05484011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: odetiglucan
Description: Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
Study NCT05484011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: A fully human agonist anti-CD40 monoclonal antibody
Study NCT05912192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonide Nasal Spray
Description: 50mcg/dose One puff for each nostrils twice daily
Study NCT05912192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray
Description: 50mcg/dose One puff for each nostrils twice daily
Study NCT05912192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily